Company Overview and News


Add RGS
to your dashboard

Headline News

Regeneus finds impressive pain relief properties in Sygenus

2017-09-27 proactiveinvestors.com.au
Regeneus (ASX:RGS) has revealed study results that highlight its Sygenus technology as showing a more potent and longer lasting effect on pain than morphine.

Regeneus Ltd granted acne patent in U.S. for Sygenus

2017-07-11 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) has been issued a notice of allowance by the United States Patent Office for a patent related to Sygenus for the treatment of acne.

Regeneus Ltd receives milestone payment to cap off quarter

2017-07-05 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) received its US$1 million milestone payment on June 30, 2017 for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.

Regeneus to receive cash payment for trial success

2017-06-21 proactiveinvestors.com.au
Regeneus (ASX:RGS) is set to receive a milestone payment of US$1 million for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.

Regeneus: Access latest PPT from Proactive's CEO Sessions

2017-06-19 proactiveinvestors.com.au
Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

XTEK brings Homeland Security Solutions to Proactive's Spotlight CEO Sessions

2017-06-09 proactiveinvestors.com.au
The company provides a wide range of specialised products in the areas of Explosive Ordinance Disposal, Unmanned Aerial Systems and imagery, weapons/ballistic protection.

AuKing Mining delivers Mexican gold-silver to Proactive's CEO Sessions

2017-06-08 proactiveinvestors.com.au
AuKing Mining (ASX:AKN) has undergone a transformation change by acquiring an interest in a high-grade gold-silver project in Mexico.

Pioneer Resources brings demand driven commodities to Proactive's CEO Sessions

2017-06-05 proactiveinvestors.com.au
Pioneer Resources (ASX:PIO) holds a portfolio of projects in Australian and Canada which are prospective for key global demand-driven commodities.

Tlou Energy's Tony Gilby brings Southern African power pathway to Proactive's CEO Sessions

2017-06-02 proactiveinvestors.com.au
Tlou Energy (ASX:TOU, AIM:TLOU) is aiming to monetise the company's gas assets through the supply of power to Botswana and Southern Africa, with the potential for the first gas-to-power by 2019.

Regeneus brings stem cell technology to Proactive's CEO Sessions

2017-06-02 proactiveinvestors.com.au
Regeneus (ASX:RGS) flagship asset is a patented off-the-shelf stem cell technology for the treatment of knee osteoarthritis and other inflammatory conditions.

Regeneus granted key Progenza patent in Japan

2017-05-24 proactiveinvestors.com.au
Regeneus (ASX:RGS) has been granted a key patent covering the composition, manufacture and use of Progenza stem cell technology in Japan.

Regeneus advances knee osteoarthritis trial

2017-05-23 proactiveinvestors.com.au
Regeneus (ASX: RGS) has successfully met its primary endpoint of safety and tolerability for its Phase 1 safety trial of the off-the-shelf stem cell treatment Progenza in patients with knee osteoarthritis (OA).

Regeneus aligns itself with Japan’s big future

2017-04-28 proactiveinvestors.com.au
Regeneus (ASX:RGS), last week, took part in a in Austrade’s business delegation to Japan, which saw John Martin, CEO, present to over 60 pharmaceutical and healthcare companies.

Regeneus CEO taking part in delegation to Japan

2017-04-18 proactiveinvestors.com.au
Regeneus (ASX:RGS) CEO John Martin  will be participating in Austrade’s business delegation to Japan on April 18 and 19 being led by Australia’s minister for trade, tourism and investments.

Regeneus reports first half-year profit, funded for eighteen months

2017-02-27 proactiveinvestors.com.au
Regeneus (ASX:RGS) reported a $3.8 million profit in the first half of FY17 after coming off a $3.1 million loss in FY16.

Regeneus receives cash payment from Japan partner

2017-01-23 proactiveinvestors.com.au
The strategic collaboration and licensing agreement recently entered into is for the manufacture, clinical development and commercialisation of Progenza in Japan.

Regeneus enters 2017 backed by transformational Japan deal

2017-01-19 proactiveinvestors.com.au
Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.

Regeneus teams up with world-leading manufacturer in Japan

2016-12-28 proactiveinvestors.com.au
Regeneus (ASX:RGS) has  entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in the Japanese market.

Regeneus enters strategic collaboration

2016-12-28 proactiveinvestors.com.au
Regeneus requested the halt pending details on the signing of transaction documents and information relating to the entry into a strategic collaboration and licensing agreement for Progenza stem cell technology in Japan.

Regeneus Ltd receives $2.7M for regenerative medicine product pipeline

2016-09-15 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Regeneus Ltd secures patent in Europe to tackle $3B acne market

2016-08-10 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Regeneus Ltd on track for Japanese commercial partnership agreement

2016-07-10 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Regeneus Ltd wins research grant for stem cell treatment of chronic pain

2016-05-19 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Regeneus Ltd completes enrolment, positive safety review in stem cell trial

2016-05-16 proactiveinvestors.com.au
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Appendix 4C - Quarterly

2016-04-28 asx.com.au